Sage Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 10
- Market Cap
- $495.1M
- Website
- http://www.sagerx.com
- Introduction
Sage Potash Corp is engaged in the acquisition, exploration, and development of mineral properties. Its principal business activity is the acquisition, exploration, and development of potash mineral properties. It holds interest in Sage Plain Potash property. The projects of the company include Sage Potash and Sage Lithium.
A Study to Assess the Electrophysiology, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response Using Magnetic Resonance Imaging of SAGE-718 Using a Ketamine Challenge in Healthy Subjects
- First Posted Date
- 2018-12-10
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Sage Therapeutics
- Target Recruit Count
- 19
- Registration Number
- NCT03770780
- Locations
- 🇺🇸
Sage Investigational Site, Berlin, New Jersey, United States
A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)
- First Posted Date
- 2018-09-11
- Last Posted Date
- 2022-08-11
- Lead Sponsor
- Sage Therapeutics
- Target Recruit Count
- 28
- Registration Number
- NCT03665038
- Locations
- 🇺🇸
Sage Investigational Site, League City, Texas, United States
A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)
- Conditions
- Interventions
- First Posted Date
- 2016-10-21
- Last Posted Date
- 2022-01-28
- Lead Sponsor
- Sage Therapeutics
- Target Recruit Count
- 138
- Registration Number
- NCT02942004
- Locations
- 🇺🇸
Sage Investigational Site, Orem, Utah, United States
A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)
- First Posted Date
- 2016-10-21
- Last Posted Date
- 2022-01-28
- Lead Sponsor
- Sage Therapeutics
- Target Recruit Count
- 108
- Registration Number
- NCT02942017
- Locations
- 🇺🇸
Sage Investigational Site, Orem, Utah, United States
A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2022-01-27
- Lead Sponsor
- Sage Therapeutics
- Target Recruit Count
- 21
- Registration Number
- NCT02614547
- Locations
- 🇺🇸
Sage Investigational Site, Philadelphia, Pennsylvania, United States
A Study With SAGE-547 for Super-Refractory Status Epilepticus
- Conditions
- Interventions
- First Posted Date
- 2015-06-23
- Last Posted Date
- 2022-01-28
- Lead Sponsor
- Sage Therapeutics
- Target Recruit Count
- 132
- Registration Number
- NCT02477618
- Locations
- 🇺🇸
Sage investigational Site, San Antonio, Texas, United States
🇬🇧Sage Investigational Site, Stoke-on-Trent, United Kingdom
An Open Label, Expanded Access Protocol With SAGE-547 for Super-Refractory Status Epilepticus
- Conditions
- First Posted Date
- 2015-05-04
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- Sage Therapeutics
- Registration Number
- NCT02433314
Evaluate SAGE-547 in Female Participants With Severe Postpartum Depression
- First Posted Date
- 2014-11-07
- Last Posted Date
- 2022-01-27
- Lead Sponsor
- Sage Therapeutics
- Target Recruit Count
- 4
- Registration Number
- NCT02285504
- Locations
- 🇺🇸
Sage Investigational Site, Chapel Hill, North Carolina, United States
Evaluate SAGE-547 in Participants With Essential Tremor
- First Posted Date
- 2014-10-28
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- Sage Therapeutics
- Target Recruit Count
- 25
- Registration Number
- NCT02277106
- Locations
- 🇺🇸
Sage Study Site, Raleigh, North Carolina, United States
Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus
- First Posted Date
- 2014-02-03
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- Sage Therapeutics
- Target Recruit Count
- 25
- Registration Number
- NCT02052739
- Locations
- 🇺🇸
Sage Investigational Site, Temple, Texas, United States